News Wire

A new report assesses how the nation fared against an ambitious challenge goal set by the American Cancer Society in 1996—reducing the cancer death rate by 50% over the 25 years ending in 2015.  The report finds areas where progress was substantial and areas where it was not.

The results of two phase 3 studies demonstrate the immunogenicity of Trumenba (meningococcal group B vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe, Pfizer Inc. has announced.

A vaccine against one of the most dangerous hospital germs may be available in the near future. Scientists in Germany have developed a substance that elicits an immune response against the gut bacterium Clostridium difficile.

Positive results have been reported from a phase 3, randomized, double-blind study of delafloxacin (Baxdela, Melinta Therapeutics), an investigational anionic quinolone in development for the treatment of patients with acute bacterial skin and skin-structure infections (ABSSSIs).

Selumetinib (AstraZeneca), an investigational MEK 1/2 inhibitor, has received orphan drug status from the FDA for the adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC). In July 2015, selumetinib failed to meet its goal in a late-stage trial for uveal melanoma, a rare eye cancer.

The medical profession must play a lead role in reversing the opioid epidemic that, far too often, has started from a prescription pad, according to Steven J. Stack, MD, president of the American Medical Association. Stack made his comments in a blog posted on the Huffington Post website.

Executives at Chiasma, a Massachusetts-based biopharmaceutical company, plan to challenge the FDA over its rejection of the company’s new drug application (NDA) for octreotide (Mycapssa), an oral maintenance treatment for adults with acromegaly, according to an article posted on the BioSpace website.

Providers across the United States have expressed misgivings about the Obama administration’s plan to rewire how Medicare pays for outpatient drugs, and the Center for Medicare and Medicaid Services (CMS) is under intense pressure to scrap it, according to an article posted on the Modern Healthcare website.

At 18.5%, Hawaii has the lowest adult obesity rate in the United States, followed by Colorado at 19.8%, according to a new Gallup survey. They are the only two states in which the obesity rate is below 20%. West Virginia has the highest adult obesity rate, at 37.0%. In addition, at least one in three adults is obese in Mississippi, Delaware, Arkansas, and Oklahoma.

The FDA has approved an expansion to the prescribing information for ibrutinib (Imbruvica, Janssen/AbbVie) based on data supporting its use in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

A genetically engineered adenovirus vaccine designed to treat patients with colon cancer has more than doubled the survival rate, with little or no toxicity, in subjects with end-stage disease, with some subjects still alive more than five years after receiving only the vaccine. The new phase 2 data were presented by Dr.

The FDA has warned that the antipsychotic medication olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body. The agency is adding a new warning that describes this severe condition, known as DRESS (drug reaction with eosinophilia and systemic symptoms), to the drug labels for all olanzapine-containing products.

The U.S. Preventive Services Task Force (USPSTF) has reiterated its recommendation that all women planning to or who could become pregnant should take a daily supplement containing 400 to 800 mcg of folic acid to help prevent neural tube defects.  The USPSTF issued a similar recommendation in 2009.

An experimental therapy stops aggressive, treatment-resistant, and deadly brain cancers called glioblastoma and high-grade gliomas in laboratory tests on human cells and in mouse models, researchers report in the journal Cancer Cell.

As part of its drive to slow the development of antimicrobial resistance, the FDA has revised annual reporting requirements for all antimicrobials sold or distributed for use in animals intended for human consumption or food-producing animals.